论文部分内容阅读
近年来,二肽基肽酶-4(DPP-4)抑制剂作为新型的口服降糖药受到广泛的关注,其主要通过改善胰岛功能异常而改善血糖控制。临床研究表明,DPP-4抑制剂与二甲双胍的联合治疗可给2型糖尿病患者带来更多益处。本文将从有效性方面进行讨论。1对象与方法1.1对象:选取2011年9月至2012年9月就诊的60例新诊断的2型糖尿病患者(符合1999年世界卫生组织诊断标准),男性38例,女性22例,年
In recent years, as a new oral hypoglycemic agent, dipeptidyl peptidase-4 (DPP-4) inhibitors have received widespread attention and have been shown to improve glycemic control primarily by ameliorating pancreatic islet dysfunction. Clinical studies have shown that combination therapy with DPP-4 inhibitors and metformin offers additional benefits for people with type 2 diabetes. This article will be discussed in terms of effectiveness. 1 Subjects and Methods 1.1 Subjects: Select 60 newly diagnosed type 2 diabetic patients (in line with the 1999 WHO diagnostic criteria) from September 2011 to September 2012, 38 males and 22 females